Levetiracetam monotherapy for late poststroke seizures in the elderly.

Department of Neurology, Ankara Research and Training Hospital, Ministry of Health, Ankara, Turkey.
Epilepsy & Behavior (Impact Factor: 2.06). 07/2008; 13(3):542-4. DOI: 10.1016/j.yebeh.2008.04.025
Source: PubMed

ABSTRACT Stroke is the most common cause of seizures in the elderly. Antiepileptic drugs are used to treat most patients with late poststroke seizures. The aim of this study was to evaluate the efficacy and tolerability of levetiracetam (LEV) in patients aged 60 or older with late-onset poststroke seizures. This prospective study evaluated patients 60 years of age or older, who had at least two late-onset poststroke seizures and were given LEV monotherapy. Demographic data and seizure and stroke characteristics were recorded. Outpatient visits were made after 2, 4, 6, 9, and 12 months and every 3 months thereafter, and the effectiveness and tolerability of LEV were investigated. Thirty-four patients with a mean age of 69.76+/-6.41 were included in this study. Average seizure frequency before treatment was 3.61+/-3.02/month. Mean follow-up time was 17.68+/-3.24 months. At daily doses of 1000-2000 mg, 82.4% of the patients were seizure free, and 7 patients (20.6%) had side effects. LEV was discontinued in one patient because of severe somnolence. Two patients were switched to another antiepileptic drug because of uncontrolled seizures despite an increase in dose up to 3000 mg/day. LEV monotherapy can be effective and well tolerated in elderly patients with late-onset poststroke seizures.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Levetiracetam (LEV) is an anti-epileptic drug commonly used for the treatment of partial onset and generalized seizures. In addition to its neuromodulatory and neuroinhibitory effects via its binding to the synaptic vesicle protein SV2A, multiple studies have suggested neuroprotective properties for LEV in both epileptic and non-epileptic conditions. The purpose of this review is to discuss the extent of LEV-mediated protection seen in different neurological conditions, the potential of LEV for easing epileptogenesis, and the possible mechanisms that underlie the protective properties of LEV. LEV has been found to be particularly beneficial for restraining seizures in animal models of spontaneous epilepsy, acute seizures, and status epilepticus (SE). However, its ability for easing epileptogenesis and cognitive dysfunction following SE remains controversial with some studies implying favorable outcomes and others reporting no beneficial effects. Efficacy of LEV as a neuroprotective drug against traumatic brain injury (TBI) has received much attention. While animal studies in TBI models have showed significant neuroprotection and improvements in motor and memory performance with LEV treatment, clinical studies suggest that LEV has similar efficacy as phenytoin in terms of its ability to prevent post-traumatic epilepsy. LEV treatment for TBI is also reported to have fewer adverse effects and monitoring considerations but electroencephalographic recordings suggest the presence of increased seizure tendency. Studies on stroke imply that LEV is a useful alternative to carbamazepine for preventing post-stroke seizures in terms of efficacy and safety. Thus, LEV treatment has promise for restraining SE-, TBI-, or stroke-induced chronic epilepsy. Nevertheless, additional studies are needed to ascertain the most apt dose, timing of intervention, and duration of treatment after the initial precipitating injury and the mechanisms underlying LEV-mediated beneficial effects.
    Frontiers in Neurology 01/2013; 4:172.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common hereditary small-vessel disease. CADASIL is caused by mutations in the NOTCH3 gene on chromosome 19; its global incidence and prevalence are unknown, likely because of under-diagnosis. CADASIL is a multisystemic disease, but its main clinical manifestations are related to the involvement of the brain. Very few controlled studies have been specifically performed on therapeutic interventions for CADASIL and its clinical manifestations. Areas covered: Evidence is reviewed about possible effects of controlling risk factors for the disease, and about treatment of most common clinical manifestations: migraine, TIA/stroke, psychiatric disturbances and epilepsy, cognitive impairment and dementia. Expert opinion: Correction of risk factors, and in particular hypertension, seems to be mandatory for reducing risk of stroke. Antiplatelet agents in secondary prevention in CADASIL might be recommended for secondary but not for primary prevention. Antiepileptic drugs seem to be the best choice for prophylaxis of migraine and MA, when needed. Psychiatric symptoms should be treated with conventional drugs, after reaching correct clinical diagnosis. Treatment of cognitive impairment and dementia with cholinesterase inhibitors may be effective on executive functions, but no conclusive data are available about its usefulness.
    Expert Opinion on Orphan Drugs. 08/2013; 1(9).
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The armamentarium to treat epilepsy includes today more than twenty drugs. These are classically distinguished as standard, traditional or first generation antiepileptic drugs (AEDs), which include phenobarbital, phenytoin, carbamazepine, valproic acid, ethosuximide and benzodiazepines, and new or second generation AEDs, which are vigabatrin, lamotrigine, felbamate, gabapentin, oxcarbazepine, tiagabine, topiramate, stiripentol, pregabalin, levetiracetam, rufinamide, zonisamide. More recently, other four compounds have been introduced, i.e., lacosamide, retigabine, eslicarbazepine acetate and perampanel, also defined as third generation AEDs. The mechanism of antiepileptic action is mainly mediated by increase in inhibitory GABA activity and/or prolongation of sodium and/or calcium channel inactivation. From a pharmacokinetic point of view, the most relevant difference characterizing a number of the recent AEDs as compared to the traditional ones is the lack of or a milder induction of hepatic enzymes with consequent reduced risk of drug-drug interactions. Concerning therapeutic features, valproic acid exhibits the broadest spectrum of action and still remains the only AED which can be used to treat all types of seizures, from absences and other primarily generalized seizures to focal ones, and almost all syndromes. Among the recent compounds, lamotrigine, topiramate, levetiracetam and zonisamide have shown to be efficacious in primarily generalized seizures and in some idiopathic generalized epilepsies, but their effect against absence seizures is less potent than that of valproic acid or even irrelevant. All AEDs, except ethosuximide, exhibit similar efficacy against focal seizures and, apart from traditional drugs, lamotrigine, oxcarbazepine, gabapentin, topiramate and levetiracetam, and ZNS in Europe, have the indication of mono-therapy. Some of the new compounds have specific paediatric indications: vigabatrin against infantile spasms in West syndrome, felbamate and rufinamide against mixed seizures in the Lennox-Gastaut syndrome, and stiripentol against some types of seizures in Dravet syndrome. In spite of this variety of AEDs, the percentage of patients with refractory epilepsy has not changed over the last 50 years and is still stabilized around 30-40%. Adverse events are observed in one-third of patients on AED therapy. Frequent, unspecific and usually dose dependent CNS side effects occur with almost all AEDs and encompass sedation, somnolence, fatigue, and dizziness, usually attenuating or even disappearing over time. Acute idiosyncratic effects, such as skin rush, may be particularly troubling and may configure a hypersensitivity syndrome with rapid degeneration to a severe and even life-threatening condition. Felbamate and vigabatrin are used exceptionally because of high incidence of aplastic anemia and liver failure occurring with the first and irreversible loss of visual field occurring with the second one. Subtle and slowly developing adverse effects, like bone mineral density reduction associated especially with traditional enzyme-inducing AEDs, require a continuous monitoring of the patient clinical condition. Antiepileptic therapy has special implications for women of child bearing age with regard to contraception, pregnancy and teratogenicity. There is some evidence that teratogenic effects, particularly frightening with valproic acid, with > 400mg/day dose of carbamazepine, and with polytherapies, are less frequent with lamotrigine. Given the large number of available AEDs, opportunities to tailor drug therapy on the individual patient are various. Treatment decisions, however, are complex and need to be individualised on the basis of careful evaluation of a number factors related to drug, disease and the patient. Choice of first-line therapy for a specific form of epilepsy, the time at which the drug should be started, and which strategy is most appropriate after failure of the first drug are key decision steps. Patient-specific factors include age, sex, childbearing potential, co-morbidities, and concomitant medications. Future directions include discovery of drugs with an improved safety profile, with more potent anti-seizure effect, able to prevent epileptogenesis and, possibly, to interact with specific genetic substrates.
    Frontiers in Clinical Drug Research - CNS and Neurological Disorders, Volume 1 edited by Atta-ur-Rahman, 09/2013: chapter 6: pages 149-229; Bentham Science Publishers., ISBN: 9781608057597


Available from
May 20, 2014